Loading...

Home
ETF
ARVN

ARVN

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

ARVN News

Arvinas, Inc. Q4 2025 Earnings Call Insights

Feb 24 2026seekingalpha

Arvinas Reports Q4 Earnings Miss with Significant Revenue Decline

Feb 24 2026seekingalpha

Arvinas Scheduled to Announce Q4 Earnings on February 24

Feb 23 2026seekingalpha

Arvinas Appoints New CEO Randy Teel Amid 11% Stock Drop

Feb 12 2026stocktwits

Arvinas Appoints New CEO and Board Chair

Feb 12 2026seekingalpha

Analysis of Rapid Growth in the PROTAC Market

Feb 10 2026Newsfilter

Arvinas Initiates ARV-393 and Glofitamab Combination Trial for DLBCL Expected in 2026

Dec 06 2025Globenewswire

Arvinas Initiates ARV-393 and Glofitamab Combination Trial for DLBCL, Expected in 2026

Dec 06 2025Newsfilter

Arvinas to Participate in Piper Sandler Healthcare Conference on December 4

Nov 26 2025Globenewswire

Arvinas Unveils Preclinical Findings for ARV-806 Showcasing Strong and Unique Efficacy in KRAS G12D-Mutated Cancer Models at the 2025 AACR-NCI-EORTC Conference on Molecular Targets and Cancer Treatments

Oct 24 2025Newsfilter

Patient-Reported Outcomes from the VERITAC-2 Trial Indicate Clinical Benefits of Vepdegestrant for Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer After Endocrine Therapy

Oct 20 2025Newsfilter

Looking Ahead: 7 Analyst Predictions for Arvinas

Oct 15 2025Benzinga

Arvinas to Showcase Findings from the Vepdegestrant Clinical Development Program at the 2025 ESMO Congress

Oct 13 2025Newsfilter

Arvinas to Showcase Clinical Findings for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress on Parkinson's Disease and Movement Disorders®

Oct 01 2025Newsfilter

Arvinas Plans Job Reductions, Out-Licenses Vepdegestrant, and Initiates $100 Million Stock Buyback Program

Sep 18 2025NASDAQ.COM

Arvinas unveils $100 million stock buyback initiative

Sep 18 2025SeekingAlpha